Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Aug 13, 2014 (12 years ago)

Propranolol Hydrochloride Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Citations given to API supplier by the Italian Health Agency AIFA for several critical deficiencies which caused a recall of the API lot used to manufacture Propanolo HCl Injection.

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

PROPRANOLOL HYDROCHLORIDE INJECTION, USP 1 mg/mL, 1 mL Single Dose Vial, Rx only, APP Pharmaceuticals, LLC Schaumburg, IL 60173, NDC 63323-604-01

Affected NDC 63323-0604-01

Compare with the code on your package — it is the most precise check available.

Drug: Propranolol

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Propranolol
Propranolol Hydrochloride
NDC 63323-0604
1 mg/mL Injection, Solution
Intravenous
Fresenius Kabi USA, LLC Rx
Recalling firm
Fresenius Kabi USA, LLC
NDC code
63323-604-01
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1545-2014 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Propranolol recalls

See all
Class II · Moderate risk

Propranolol HCl

cGMP Deviations: GYMA laboratories Inc. has recalled multiple Active Pharmaceutical Ingredients manufactured in Italy upon receipt of a Rapid Alert Notification issued by The Italian Medicines Agency due to lack of good manufacturing practices.

Terminated cGMP deviation Gyma Laboratories Of Amer,Inc D-0022-2015
Class II · Moderate risk

Propranolol Hydrochloride Tablets

Failed Tablet/Capsule Specification: Teva is recalling certain lots of Propanolol HCl Tablets, 10 mg due to the potential of some tablets not conforming to weight specification.

Terminated Failed specification Teva Pharmaceuticals USA, Inc. NDC 50111-467-03 D-924-2013
Class II · Moderate risk

Propranolol HCL

Labeling: Label Mixup: PROPRANOLOL HCL, Tablet, 10 mg may have potentially been mislabeled as one of the following drugs: LORazepam, Tablet, 0.25 mg (1/2 of 0.5 mg), NDC 00591024001, Pedigree: AD60243_1, EXP: 5/22/2014; PROPRANOLOL HCL, Tablet, 10 mg, NDC 23155011001, Pedigree: W003068, EXP: 6/12/2014.

Terminated Labeling / mix-up Aidapak Services, LLC D-993-2014
Class II · Moderate risk

Propranolol HCL ER

Labeling: Label Mixup: PROPRANOLOL HCL ER, Capsule, 60 mg may have potentially been mislabeled as the following drug: CINACALCET HCL, Tablet, 30 mg, NDC 55513007330, Pedigree: AD52778_82, EXP: 5/21/2014.

Terminated Labeling / mix-up Aidapak Services, LLC D-885-2014

Other recalls by Fresenius Kabi USA, LLC

All 2014 recalls
Class I · High risk

Tyenne (tocilizumab-aazg)

Presence of particulate matter:An internal investigation at the firm found the product to contain glass particles.

Ongoing Particulate / foreign matter Fresenius Kabi USA, LLC NDC 65219-594-20 D-0827-2026
Class I · High risk

Morphine Sulfate Injection

Labeling: Label Mixup: MicroVault labeled as Morphine 2 mg/1 mL, contains a Prefilled Syringe of Dilaudid 0.5 mg/0.5 mL.

Ongoing Labeling / mix-up Fresenius Kabi USA, LLC D-0788-2026